Online inquiry

IVTScrip™ mRNA-Human ARF1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK23163MR)

This product GTTS-WK23163MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ARF1 protein. This product can be used in CD141+CLEC9A+ dendritic cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001024226.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 375
UniProt ID P84077
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARF1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK23163MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK10740MR IVTScrip™ mRNA-Human ADGRF5, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADGRF5
GTTS-WK22865MR IVTScrip™ mRNA-Human ARF4, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ARF4
GTTS-WK11559MR IVTScrip™ mRNA-Human ACTG1, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACTG1
GTTS-WK23807MR IVTScrip™ mRNA-Human ARHGEF10, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARHGEF10
GTTS-WK17934MR IVTScrip™ mRNA-Human ANKRD65, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANKRD65
GTTS-WK18216MR IVTScrip™ mRNA-Human ANKRD30BP2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD30BP2
GTTS-WK26270MR IVTScrip™ mRNA-Human ARPC4-TTLL3, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARPC4-TTLL3
GTTS-WK6527MR IVTScrip™ mRNA-Human CD24, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD24
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW